Drug intelligence / Profile preview

mesalazine + ciprofloxacin

Development stage
Unknown
Lead developer
Ferring Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Rectal, Intravenous, Ophthalmic, Otic
01

Overview

Mesalazine + ciprofloxacin is a combination of two pharmaceutical agents used primarily for their respective actions in inflammatory bowel disease and bacterial infections. Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory drug that acts mainly topically in the colon to treat mild to moderate ulcerative colitis and maintain remission. Its mechanism involves inhibition of prostaglandin synthesis and leukotriene pathways as well as scavenging free radicals[2]. Ciprofloxacin is a second-generation fluoroquinolone antibiotic effective against a broad range of Gram-negative and some Gram-positive bacteria by inhibiting bacterial DNA gyrase and topoisomerase IV[8]. The combination may be considered in clinical scenarios where patients with inflammatory bowel disease develop concurrent bacterial infections requiring antibiotic therapy. Clinical studies indicate no significant pharmacokinetic interaction between MMX mesalamine formulations and ciprofloxacin; both drugs can be coadministered without affecting efficacy or safety profiles[1][3][4].

Brand names
AsacolMezavantZaldyonCetraxalCiloxanCipro HCCiprodexCiprofloxacin (as a brand)OtiprioOtixalOtovelProquin
Other names
5-aminosalicylic acid + ciprofloxacin
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase15-LOX (Lysyl Oxidase)COX

Beyond the preview

Go deeper on mesalazine + ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesalazine + ciprofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call